ERBB2 and breast cancer: In this study, we evaluated the efficacy and safety of adding pyrotinib to a neoadjuvant regimen of trastuzumab plus chemotherapy in patients with HER2-positive breast cancer who did not exhibit an early response to trastuzumab-based therapy alone.